CY1113593T1 - IL-1 antagonist preparations - Google Patents

IL-1 antagonist preparations

Info

Publication number
CY1113593T1
CY1113593T1 CY20131100092T CY131100092T CY1113593T1 CY 1113593 T1 CY1113593 T1 CY 1113593T1 CY 20131100092 T CY20131100092 T CY 20131100092T CY 131100092 T CY131100092 T CY 131100092T CY 1113593 T1 CY1113593 T1 CY 1113593T1
Authority
CY
Cyprus
Prior art keywords
antagonist
seq
lyophilized formulation
antagonist preparations
preparations
Prior art date
Application number
CY20131100092T
Other languages
Greek (el)
Inventor
Daniel Dix
Katherine Bowers
Goolcharran Chimanlall
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05789252A external-priority patent/EP1778723B1/en
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of CY1113593T1 publication Critical patent/CY1113593T1/en

Links

Abstract

Παρέχονται σκευάσματα ανταγωνιστή ιντερλευκίνης-1 (IL-1) που περιλαμβάνουν προ-λυοφιλιωμένο σκεύασμα, ανασυστημένο λυοφιλιωμένο σκεύασμα, και σταθερό υγρό σκεύασμα. Κατά προτίμηση, ο ανταγωνιστής IL-1 είναι IL-1 trap αποτελούμενη από διμερές δύο συντηγμένων πρωτεϊνών που έχει αλληλουχία αμινοξέων που επιλέγεται από την ομάδα που αποτελείται από αλληλουχία αρ. (SEQ ID NO:) 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, και 26. Πλέον προτιμότερα, η συντηγμένη πρωτεΐνη έχει την αλληλουχία της αλληλουχίας αρ. 10.Interleukin-1 antagonist (IL-1) formulations are provided which comprise a pre-lyophilized formulation, reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the IL-1 antagonist is an IL-1 trap consisting of a dimer of two fusion proteins having an amino acid sequence selected from the group consisting of SEQ ID NO: 1. (SEQ ID NO :) 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 26. Most preferably, the fusion protein has the sequence SEQ ID NO: 2. 10.

CY20131100092T 2004-08-17 2013-02-01 IL-1 antagonist preparations CY1113593T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60213704A 2004-08-17 2004-08-17
EP05789252A EP1778723B1 (en) 2004-08-17 2005-08-17 Il-1 antagonist formulations

Publications (1)

Publication Number Publication Date
CY1113593T1 true CY1113593T1 (en) 2016-06-22

Family

ID=58448871

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100092T CY1113593T1 (en) 2004-08-17 2013-02-01 IL-1 antagonist preparations

Country Status (1)

Country Link
CY (1) CY1113593T1 (en)

Similar Documents

Publication Publication Date Title
CY1119243T1 (en) VEGF COMPONENT PHARMACEUTICAL FORMS
WO2006023665A3 (en) Il-1 antagonist formulations
CY1114244T1 (en) VEGF COMPONENT COMPONENTS FOR SUITABLE INTERVENTAL ADMINISTRATION
AR038568A1 (en) ANTI-A BETA ANTIBODIES AND ITS USE
DE50112802D1 (en) PEPTIDES, THEIR PREPARATION AND USE OF THE BINDING OF IMMUNE LOBULINS
CY1118443T1 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES
EA200400241A1 (en) MULTIMERAL CONTRAST SUBSTANCES BASED ON PEPTIDES ARE DIRECTED TO A TARGET
NO20054440L (en) Liquid formulations of tumor necrosis factor binding proteins
ES2149149T1 (en) INTERLEUKIN-18 FIXING PROTEINS, THEIR PREPARATION AND USE.
BRPI0519705A2 (en) compositions, fusion proteins and methods of stimulating an immune response in an individual
EA200802170A1 (en) LYOPHILIZED COMPOSITION OF THERAPEUTIC PEPTIDE ANTIBODY
PE20040554A1 (en) VACCINES INVOLVING FUSION PROTEINS
DE602004011770D1 (en) FUSION PROTEIN
EA200300381A1 (en) NUCLEIC ACIDS AND POLYPEPTIDES OF THE NEW RECEPTOR
DE60144145D1 (en) Subtilisin variant
CY1105616T1 (en) PEPTIDE INHIBITORS OF TGFβ1
WO2006052821A3 (en) Compositions and methods for treatment of protein misfolding and protein aggregation diseases
BR0012919A (en) Vaccine for use in the prophylaxis and / or treatment of white spot syndrome in crustaceans, structural protein derived from white point syndrome virus, nucleic acid sequence, use of a structural protein, pharmaceutical composition, antibodies, vaccine or pharmaceutical formulation, and, diagnostic kit for wssv detection
DK1079849T3 (en) Use of HMG proteins for the preparation of drugs with cytotoxic effect
ATE551069T1 (en) MUCIN FUSION POLYPEPTIDE VACCINES, COMPOSITIONS AND USE THEREOF
NO20011537L (en) Chemokine receptor peptide vaccines for the treatment and prevention of diabetes
ITRM20030363A1 (en) COMPOSITIONS INCLUDING 3THIODOTYRONIN AND PHARMACEUTICAL USE OF THEM.
TR200400639T4 (en) Anti-freeze proteins, their production and uses
DK1219301T3 (en) Vaccines containing hybrid polypeptides consisting of at least two different allergenic proteins
CY1113593T1 (en) IL-1 antagonist preparations